GRAMD4

Across TCGA pan-cancer cohorts, GRAMD4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GRAMD4 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GRAMD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GRAMD4 expression acts as an unfavorable survival marker.

COAD, ESCA, and UCEC are the cancer types where GRAMD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GRAMD4–COAD (OS)

Open the COAD breakdown →